Mixed-metal polymetallic platinum complexes designed to interact with DNA
暂无分享,去创建一个
[1] C. Moucheron,et al. Photophysics of Ru(phen)2(PHEHAT)2+: A Novel “Light Switch” for DNA and Photo-oxidant for Mononucleotides , 1997 .
[2] M R Arkin,et al. Rates of DNA-Mediated Electron Transfer Between Metallointercalators , 1996, Science.
[3] K. Brewer,et al. Spectroscopic and Electrochemical Properties of a Series of Mixed-Metal d6,d8 Bimetallic Complexes of the Form [(bpy)2M(BL)PtCl2]2+ (bpy = 2,2‘-Bipyridine; BL = dpq (2,3-Bis(2- pyridyl)quinoxaline) or dpb (2,3-Bis(2-pyridyl)- benzoquinoxaline); M = OsII or RuII) , 1996 .
[4] Huifang Huang,et al. Solution Structure of a Cisplatin-Induced DNA Interstrand Cross-Link , 1995, Science.
[5] R. Perez,et al. Cytotoxicity, cellular accumulation and DNA binding of oxaliplatin isomers. , 1995, Cancer letters.
[6] S. Lippard,et al. Crystal structure of double-stranded DNA containing the major adduct of the anticancer drug cisplatin , 1995, Nature.
[7] N. Turro,et al. Proton Transfer Quenching of the MLCT Excited State of Ru(phen)2dppz2+ in Homogeneous Solution and Bound to DNA , 1995 .
[8] D. McMillin,et al. DNA-Binding Studies of a Bifunctional Platinum Complex That Is a Luminescent Intercalator , 1995 .
[9] R. Baan,et al. Formation of DNA adducts by the anticancer drug carboplatin: different nucleotide sequence preferences in vitro and in cells. , 1995, Biochemistry.
[10] J. Barton,et al. Os(phen)2(dppz)2+: A Red-Emitting DNA Probe , 1995 .
[11] L. Marzilli,et al. DNA Adduct Formation by Platinum Anticancer Drugs. Insight into an Unusual GpG Intrastrand Cross-Link in a Hairpin-like DNA Oligonucleotide Using NMR and Distance Geometry Methods , 1994 .
[12] B. Van Houten,et al. Sequence specificity of DNA-DNA interstrand cross-link formation by cisplatin and dinuclear platinum complexes. , 1994, Biochemistry.
[13] H. Homesley,et al. Cancers of the uterine cervix and endometrium: major issues and future research directions. , 1994, Seminars in oncology.
[14] A. Khokhar,et al. Circumvention of platinum resistance: structure-activity relationship for homologous series of ammine/amine platinum(II) complexes in L1210 cell lines. , 1994, Anti-cancer drug design.
[15] B. Van Houten,et al. Ligand effects on platinum binding to DNA. A comparison of DNA binding properties for cis- and trans-[PtCl2(amine)2] (amine = NH3, pyridine). , 1993, Biochemistry.
[16] R. Sheardy,et al. A new class of DNA metallobinders showing spectator ligand size selectivity: binding of ligand-bridged bimetallic complexes of ruthenium(II) to calf thymus DNA , 1993 .
[17] G. Zon,et al. DNA hairpin formation in adducts with platinum anticancer drugs: gel electrophoresis provides new information and a caveat , 1993 .
[18] Y. Fujiwara,et al. A new anticancer platinum compound, (-)-(R)-2-aminomethyl-pyrrolidine(1,1-cyclobutanedicarboxylato) platinum(II): DNA interstrand crosslinking, repair and lethal effects in normal human, Fanconi's anaemia and xeroderma pigmentosum cells. , 1993, British Journal of Cancer.
[19] N. Turro,et al. Characterization of dipyridophenazine complexes of ruthenium(II): the light switch effect as a function of nucleic acid sequence and conformation. , 1992, Biochemistry.
[20] P. O'Connor,et al. Increased gene-specific repair of cisplatin interstrand cross-links in cisplatin-resistant human ovarian cancer cell lines , 1992, Molecular and cellular biology.
[21] J. Barton,et al. Novel dipyridophenazine complexes of ruthenium(II): exploring luminescent reporters of DNA , 1992 .
[22] L. Orgel,et al. An efficient, sequence-specific method for crosslinking complementary oligonucleotides using binuclear platinum complexes. , 1991, Nucleic acids research.
[23] B. Van Houten,et al. Comparison of chemical reactivity, cytotoxicity, interstrand cross-linking and DNA sequence specificity of bis(platinum) complexes containing monodentate or bidentate coordination spheres with their monomeric analogues. , 1990, Biochemistry.
[24] Christopher A. Lepre,et al. Platinum-195 NMR kinetic and mechanistic studies of cis- and trans-diamminedichloroplatinum(II) binding to DNA , 1990 .
[25] John D. Roberts,et al. Interaction of novel bis(platinum) complexes with DNA. , 1989, Nucleic acids research.
[26] J. Barton,et al. Metal-activated hydrolytic cleavage of DNA , 1987 .
[27] S. Lippard,et al. Structural aspects of platinum anticancer drug interactions with DNA , 1987 .
[28] P. Lohman,et al. Adducts of the antitumor drug cis-diamminedichloroplatinum(II) with DNA: formation, identification, and quantitation. , 1985, Biochemistry.
[29] P. Lohman,et al. Induction and repair of DNA cross-links in chinese hamster ovary cells treated with various platinum coordination compounds in relation to platinum binding to DNA, cytotoxicity, mutagenicity, and antitumor activity. , 1984, Cancer research.
[30] J. Sambrook,et al. Molecular Cloning: A Laboratory Manual , 2001 .
[31] F. Friedlos,et al. The frequency of interstrand cross-links in DNA following reaction of cis-diamminedichloroplatinum(II) with cells in culture or DNA in vitro: stability of DNA cross-links and their repair. , 1982, Chemico-biological interactions.